PXS Insider Trading

Insider Ownership Percentage: 17.33%
Insider Buying (Last 12 Months): A$103,348.35
Insider Selling (Last 12 Months): A$0.00

Pharmaxis Insider Trading History Chart

This chart shows the insider buying and selling history at Pharmaxis by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pharmaxis Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for PXS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Pharmaxis Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/2/2022Kathleen MettersInsiderIssued3,000,000A$0.06A$189,000.00
11/29/2022Gary PhillipsInsiderIssued2,771,000A$0.06A$174,573.00
11/1/2022Gary PhillipsInsiderBuy1,640,450A$0.06A$103,348.35
8/22/2022Gary PhillipsInsiderExpiry1,305,700A$0.08A$100,538.90
12/22/2021Malcolm McComasInsiderIssued285,715A$0.11A$30,000.08
11/3/2021Gary PhillipsInsiderIssued2,374,000A$0.12A$273,010.00
8/12/2021Gary PhillipsInsiderExpiry471,000A$0.10A$44,745.00
5/3/2021Malcolm McComasInsiderBuy500,000A$0.09A$43,500.00
11/4/2020Gary PhillipsInsiderIssued942,000A$0.11A$103,620.00
8/12/2020Gary PhillipsInsiderExpiry602,550A$0.11A$63,267.75
See Full Table

SEC Filings (Institutional Ownership Changes) for Pharmaxis (ASX:PXS)

37.48% of Pharmaxis stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Pharmaxis logo
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol Respiratory Business and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of oral pan-lysyl oxidase inhibitors (LOX) targeting myelofibrosis and other cancers; topical pan-LOX inhibitors targeting skin scarring after events, such as accidents, surgery,and burns; selective Lysyl Oxidase Like Inhibitors (LOXL2) targeting chronic fibrotic diseases, including kidney fibrosis, pulmonary fibrosis, liver fibrosis, and cardiac fibrosis; and semicarbazide-sensitive amine oxidase for neuro inflammatory diseases. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.
Read More on Pharmaxis

Today's Range

Now: N/A

50 Day Range


52 Week Range

Now: N/A


721,139 shs

Average Volume


Market Capitalization


P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Pharmaxis?

Pharmaxis' top insider investors include:
  1. Gary Phillips (Insider)
  2. Kathleen Metters (Insider)
  3. Malcolm McComas (Insider)
Learn More about top insider investors at Pharmaxis.